Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses.
van Eck van der Sluijs J, van Ens D, Thordardottir S, Vodegel D, Hermens I, van der Waart AB, Falkenburg JHF, Kester MGD, de Rink I, Heemskerk MHM, Borst J, Schaap NPM, Jansen JH, Xiao Y, Dolstra H, Hobo W.
van Eck van der Sluijs J, et al. Among authors: van der waart ab.
Cancer Immunol Immunother. 2021 Nov;70(11):3167-3181. doi: 10.1007/s00262-021-02899-3. Epub 2021 Apr 1.
Cancer Immunol Immunother. 2021.
PMID: 33796917
Free PMC article.